Showing results (251-260 of 376) with videos related to

Sort By:
Pageof 38
HIV Clinical Trials|May 18, 2012
Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 studyJosé A Pérez-Molina, Marta Mora Rillo, Ignacio Suárez-Lozano, et al.
The Journal of Infection|July 16, 2003
Hepatitis C virus and human immunodeficiency virus coinfection in SpainBernardino Roca, Ignacio Suarez, Juan Gonzalez, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.
Plos One|December 3, 2014
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individualsMarta Massanella, Dan Ouchi, Silvia Marfil, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2024
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudineElisa de Lazzari, Eugenia B Negredo, Pere Domingo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 9, 2006
Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjectsConsuelo Viladés, Montserrat Broch, Montserrat Plana, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|January 13, 2024
The impact of the COVID-19 pandemic on healthcare services utilization among people living with HIV in Catalonia, Spain: A population-based cohort studyYi-Hua Pan, Daniel K Nomah, Marcos Montoro-Fernandez, et al.
Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
Clinical Immunology (Orlando, Fla.)|November 15, 2020
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohortHèctor Corominas, Ivan Castellví, Virginia Pomar, et al.
HIV Clinical Trials|October 23, 2013
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP studyJosé Ramón Blanco, Ana María Caro-Murillo, Manuel Angel Castaño, et al.
Pageof 38